4-carbamoylimidazolium 5-olate has been researched along with Granulocytic Leukemia, Chronic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujita, J; Hata, Y; Ikeda, K; Irino, S; Kamano, H; Shiotani, T; Takahara, J; Yamaji, Y | 1 |
Hirano, M; Kimura, K; Masaoka, T; Ogawa, M; Ohno, R; Uzuka, Y; Yamada, K | 1 |
1 trial(s) available for 4-carbamoylimidazolium 5-olate and Granulocytic Leukemia, Chronic
Article | Year |
---|---|
[Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Child; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Imidazoles; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Lymphoma; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Polycythemia Vera; Remission Induction | 1989 |
1 other study(ies) available for 4-carbamoylimidazolium 5-olate and Granulocytic Leukemia, Chronic
Article | Year |
---|---|
Induction of erythroid differentiation of K562 cells by 4-carbamoylimidazolium 5-olate (SM-108).
Topics: Cell Differentiation; Cell Line; Erythrocytes; Guanosine Triphosphate; Humans; Imidazoles; IMP Dehydrogenase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Purines; Tumor Stem Cell Assay; Xanthine; Xanthines | 1991 |